ArticlePloS one2015
A bioengineered nisin derivative to control biofilms of Staphylococcus pseudintermedius.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 76 citations in OpenAlex.
- Bacteriocin diversity, function, discovery and application as antimicrobials.Nature reviews. Microbiology · 2024Review
- Antimicrobial Strategies Proposed for the Treatment ofVeterinary sciences · 2024Review
- Combination antimicrobial therapy: in vitro synergistic effect of anti-staphylococcal drug oxacillin with antimicrobial peptide nisin against Staphylococcus epidermidis clinical isolates and Staphylococcus aureus biofilms.Annals of clinical microbiology and antimicrobials · 2024Article
- Screening canine sources for novel antimicrobials reveals the circular broad-spectrum bacteriocin, caledonicin, produced byFrontiers in microbiology · 2024Article
- Understanding the Influence of Rheology on Biofilm Adhesion and Implication for Food Safety.International journal of food science · 2024Review
- Evaluating the Translational Potential of Bacteriocins as an Alternative Treatment forAntibiotics (Basel, Switzerland) · 2023Review
- After a century of nisin research - where are we now?FEMS microbiology reviews · 2023Review
- Bioengineered Nisin A Derivatives Display Enhanced Activity against Clinical Neonatal Pathogens.Antibiotics (Basel, Switzerland) · 2022Article
- Nisin Variants Generated by Protein Engineering and Their Properties.Bioengineering (Basel, Switzerland) · 2022Review
- Demystifying Bacteriocins of Human Microbiota by Genome Guided Prospects: An Impetus to Rekindle the Antimicrobial Research.Current protein & peptide science · 2022Review
- Bio-Engineered Nisin with Increased Anti-International journal of molecular sciences · 2021Article
- Virulence Factors in Coagulase-Negative Staphylococci.Pathogens (Basel, Switzerland) · 2021Review
- Prevalence and Characteristics ofFrontiers in microbiology · 2021Article
- Preventive Effects ofFrontiers in microbiology · 2021Article
- Efficacy of Phage- and Bacteriocin-Based Therapies in Combatting Nosocomial MRSA Infections.Frontiers in molecular biosciences · 2021Review
- Periodontal Disease: The Good, The Bad, and The Unknown.Frontiers in cellular and infection microbiology · 2021Review
- Recipe for Success: Suggestions and Recommendations for the Isolation and Characterisation of Bacteriocins.International journal of microbiology · 2021Review
- Bacteriocin-a potential antimicrobial peptide towards disrupting and preventing biofilm formation in the clinical and environmental locales.Environmental science and pollution research international · 2020Review
- Gram-positive bacteriocins: usage as antimicrobial agents in veterinary medicine.Veterinary research communications · 2020Review
- Bioengineered Nisin Derivative M17Q Has Enhanced Activity againstAntibiotics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance and the shortage of novel antimicrobials are among the biggest challenges facing society. One of the major factors contributing to resistance is the use of frontline clinical antibiotics in veterinary practice. In order to properly manage dwindling antibiotic resources, we must identify antimicrobials that are specifically targeted to veterinary applications. Nisin is a member of the lantibiotic family of antimicrobial peptides that exhibit potent antibacterial activity against many gram-positive bacteria, including human and animal pathogens such as Staphylococcus, Bacillus, Listeria, and Clostridium. Although not currently used in human medicine, nisin is already employed commercially as an anti-mastitis product in the veterinary field. Recently we have used bioengineering strategies to enhance the activity of nisin against several high profile targets, including multi-drug resistant clinical pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) and also against staphylococci and streptococci associated with bovine mastitis. However, newly emerging pathogens such as methicillin resistant Staphylococcus pseudintermedius (MRSP) pose a significant threat in terms of veterinary health and as a reservoir for antibiotic resistance determinants. In this study we created a nisin derivative with enhanced antimicrobial activity against S. pseudintermedius. In addition, the novel nisin derivative exhibits an enhanced ability to impair biofilm formation and to reduce the density of established biofilms. The activities of this peptide represent a significant improvement over that of the wild-type nisin peptide and merit further investigation with a view to their use to treat S. pseudintermedius infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.